Ivan S. Koklin

Ivan S. Koklin

Auto-generated profile, based on publicly available information

Ivan S. Koklin

Belgorod State National Research University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
IKIvan S. Koklin
Ivan S. Koklin
LDLyudmila Danilenko
Lyudmila Danilenko
Introduction: The concept of the regulatory role of endothelium in the pathogenesis of pulmonary hypertension (PH) is fundamental. Research objective: To study the protective effects of the selective arginase II inhibitors L207-0525 and L327-0346 in combination with tadalafil in a monocrotaline model of pulmonary hypertension in rats. Materials and methods: Monocrotaline-induced pulmonary hypertension was simulated in 10 animals by a subcutaneous injection of an alcohol-water solution of monocrotaline (MCT) in the dose of 60 mg/kg. Seven days after the injection of MCT, the administration of L207-0525 and L327-0346 in the doses of 1 mg/kg and 3 mg/kg was started. The compounds were administered intragastrically once a day for 21 days. Results and discussion: It was found that L207-0525 and L327-0346 in the dose of 3 mg/kg and tadalafil in the dose of 1 mg/kg prevented the development of pulmonary hypertension, which was expressed in a statistically significant decrease in the coefficient of endothelial dysfunction (CED, prevention of an increase in systolic pressure in the right ventricle, as well as Fulton, RV/BW and WT indices. The greatest activity was shown by L207-0525 and L327-0346 in the dose of 3 mg/kg in combination with tadalafil in the dose of 0.1 mg/kg. Conclusions: The received results suggest the dose-dependent protective activity of selective arginase II inhibitors L207-0525 and L327-0346 and the development of the additive effect of their combined use with low doses of PDE-5 inhibitor tadalafil in relation to the development of monocrotaline pulmonary hypertension.

28 April 2023 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
ADA. P. Danilenko
A. P. Danilenko
KTK. S. Trunov
K. S. Trunov
МПМ. В. Покровский
М. В. Покровский
LDLyudmila Danilenko
Lyudmila Danilenko
MKMikhail Korokin
Mikhail Korokin
ETE. I. Taran
E. I. Taran
From the point of view of the mechanisms for the implementation of pathogenetic links in the development of steroid-induced osteoporosis considered in the paper, the increased risk of the oxidative stress in osteoblasts, as well as the development of the vessels endothelial dysfunction of the microcirculatory bloodstream in the bone tissue, are of particular interest. They lead to the impaired bone tissue trophism and progression of osteoporosis.The aim of the study was research of the osteoprotective effects of a 3-hydroxypyridine derivatives composition on the model of steroid-induced osteoporosis.Materials and methods. To model osteoporosis pathology, the animals (male Wistar rats) were injected with methylprednisolone (MP) at the dose of 5 mg/kg (intraperitoneally) every 5th day for 5 weeks. Аs a non-selective blocker of NO synthase, L-NAME was used at the dose of 25 mg/kg (intraperitoneally). Derivatives of 3-hydroxypyridine (hereinafter referred to as composition No. 1) were administrated at the dose of 50 mg/kg (per os) In all experimental groups, the level of microcirculation and the bone mineral density, as well as the analysis of histomorphological and biochemical samples, were assessed.Results. The study results showed that composition No. 1 (50 mg/kg) has an osteoprotective activity, effectively prevents a decrease in the level of the regional bone tissue microcirculation and in the development of an endothelial dysfunction. That makes it possible to increase the bone mineral density and to slow down the thinning of bone trabeculae. In addition, composition No. 1 (50 mg/kg) reduces the production of reactive oxygen species and increases the NO bioavailability.Conclusion. The data obtained indicate that the studied composition of 3-hydroxypyridine derivatives is considered a promising compound for the prevention and treatment of steroid-induced osteoporosis.

4 October 2023 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
MKMikhail Korokin
Mikhail Korokin
OGOleg Gudyrev
Oleg Gudyrev
TPTatiana G. Pokrovskaya
Tatiana G. Pokrovskaya
LDLyudmila Danilenko
Lyudmila Danilenko
NZNina I. Zhernakova
Nina I. Zhernakova
ETEduard I. Taran
Eduard I. Taran
Introduction: The aim of this study was to evaluate the processes of bone remodeling and osteoreparation in modeling femoral fracture in mice with zero expression of 11β-HSD2 (11β-HSD2-/-) or both 11β-HSD2 and apolipoprotein e (11β-HSD2-/-/ApoE-/-). Materials and Methods: The experimental study was conducted on 60 male mice weighing 24-30 g. The study used male mice that lacked the expression of 11β-HSD2 (knockout mice with the Hsd2-/- genotype) and male mice that lacked the expression of 11β-HSD2 and apolipoprotein E (double knockout mice with the Hsd2-/-/ApoE-/- genotype). The control group includes wild type C57bl/6 animals. Modeling of a fracture of the proximal metaphysis of the femur was performed in animals at the age of 6 months using a closed technique. Fracture fusion and bone remodeling and osteoreparation processes were evaluated 6 weeks after fracture modeling. Results and Discussion: It has been shown that a violation of the regulation of steroid hormone metabolism in groups of animals with the Hsd2-/- and Hsd2-/-/ApoE-/- genotypes leads to an increase in the number of ungrown fractures by 3 and 3.5 times, respectively, in comparison with wild-type animals. It was found that the microcirculation level of the proximal metaphysis of the left femur in the area of the formed bone callus in the group of animals with the genotype 11β-HSD2-/- significantly decreased from 92.075±4.33 perfusion units (PE) in the group of wild-type animals to 82.67±3.54 PE (p=0.0002) in the group of animals with the genotype HSD2-/- and up to 75.85±5.64 (p<0.0001) in the group of mice with the Hsd2-/-/ApoE-/- genotype. When calculating the coefficient of endothelial dysfunction, an increase in the coefficient of endothelial dysfunction was found from 1.297±0.19 in intact animals to 2.115±0.45 (p<0.00001) in the group of mice with the Hsd2-/- genotype and to 2.41±0.04 (p<0.00001) in the group of mice with the Hsd2-/-/ApoE-/- genotype. In animals with impaired cortisol metabolism, there was a slowdown in the formation of bone tissue in the fracture area, bone trabeculae had a smaller width, large amounts of fibrous and connective tissue were observed in the lumen between bone fragments, and an increase in intertrabecular spaces was noted Conclusion: The close relationship between the metabolism of 11β-HSD2 and NO, confirmed in this study, can be considered as a promising pharmacotherapeutic target. It is obvious that approaches to changing the activity of 11β-HSD have significant therapeutic potential in the treatment of osteoporosis, bone remodeling disorders and osteoreparation in fractures against the background of formed osteoporotic changes in the violation of steroid hormone metabolism.

13 December 2022 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
MKMikhail Korokin
Mikhail Korokin
OGOleg Gudyrev
Oleg Gudyrev
PLPetr Lebedev
Petr Lebedev
EKElena Valeryevna Kuzubova
Elena Valeryevna Kuzubova
АРАлександра Радченко
Александра Радченко
AKAlim A. Kochkarov
Alim A. Kochkarov
Introduction: The aim was to evaluate the structural and functional changes of bone tissue in mice with null expression of 11β-HSD2 or both 11β-HSD2 and Apolipoprotein E. Materials and methods: The experimental study was performed in 60 male mice, weighting 24–30 g. The animals were kept in accordance with the rules of laboratory practice for preclinical studies on the territory of the Russian Federation. Mice lacking 11β-HSD2 (Hsd2-/-) and male mice lacking 11β-HSD2 and Apolipoprotein E (Hsd2-/-/Apoe-/-) were used in the study. We studied and characterized the state of bone tissue, indicators of bone density, microcircu­lation in bone tissue, endothelial dysfunction coefficient, width of bone trabeculae, as well as serum concentrations of bone alkaline phosphatase, hydroxyproline, deoxyprinoline and expression levels of p53, Bcl2, Bax, eNOS genes. Results and discussion: We showed that mice with the Hsd2-/- genotype with no expression of 11ß-HSD2 by the 6th month of life showed a statistically significant decrease in bone density, which progresses to the 7th and 8th months of life. At the 8th month of animal life, a decrease in bone density is accompanied by a statistically significant decrease in the level of microcirculation in the bone and an increase in the coefficient of endothelial dysfunction. Taking into account the relationship of endothelial dysfunction, atherogenesis and disorders in the processes of bone remodeling, in the framework of this study, we also assessed the state of bone tissue in double transgenes with the genotype Hsd2-/-/Apoe-/-, which lack the expression of both 11ß-HSD2 and Apolipoprotein E. In this study, we also saw increased acti­vation of processes leading to disruption of bone remodeling processes. In the group of the animals with the genotype Hsd2-/-/Apoe-/-, we found statistically significant differences from the mice with no expression of 11ß-HSD2 in bone density and microcirculation, and the width of bone trabeculae. Also, a statistically significant increase in hydroxypro­line and deoxyprinoline was found in the group of double transgenes, in the absence of significant changes in the con­centration of bone alkaline phosphatase. This fact indicates a pronounced activation of bone resorption processes in the absence of activation of osteosynthesis processes, which leads to the detected violation of bone remodeling processes. Conclusion: Thus, we have shown that a violation of the metabolic regulation of steroid hormone metabolism in ani­mals with null expression of the 11ß-HSD2 (Hsd2-/- genotype) leads to the development of signs of osteoporosis – bone density decreases, which is accompanied by a decrease in the width of bone trabeculae, the level of microcirculation in bone tissue decreases simultaneously with an increase in the coefficient of endothelial dysfunction. The additional null expression of ApoE gene in double transgenes with the genotype Hsd2-/-/Apoe-/- leads to an increase in the severity of changes associated with a violation of bone remodeling processes and, in addition to a more pronounced change in bone tissue density, bone trabecular width, microcirculation and the coefficient of endothelial dysfunction leads to an increase in the concentration of biochemical markers of bone resorption. These changes indicate the important role of the enzyme 11ß-hydroxysteroid dehydrogenase type 2 in the processes of bone remodeling disorders. Graphical

24 November 2025 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
MKMikhail Korokin
Mikhail Korokin
SKSvetlana K. Kotovskaya
Svetlana K. Kotovskaya
ТАТатьяна В. Автина
Татьяна В. Автина
ИКИван С. Коклин
Иван С. Коклин
Ilya ButorinIlya Butorin
Ilya Butorin
PPPolina I. Pykhtina
Polina I. Pykhtina
Introduction: Osteoporosis is an important medical and social public health problem in an aging or elderly society, the issue of pharmacological correction of which remains unresolved to this day. Materials and Methods: A design of prospective 11β-HSD1 inhibitors was performed on the basis of the literature data. A virtual screening of the designed compounds was performed using pharmacophore searching (DataWarrior, Flexophore), pharmacophore alignment (PhESA), and molecular docking (Jamda). 2D protein-ligand interaction maps were generated using PoseEdit, and 3D visualizations were produced in VMD. The cytotoxicity of the compounds was assessed in HEK-293 cells across a concentration range of 8–1024 μM, with IC50 values calculated in RStudio. Results and Discussion: A comprehensive virtual screening of prospective 11β-HSD1 inhibitors was performed, incorporating pharmacophore searching, PhESA alignment, and molecular docking against the 11β-HSD1 complex (PDB: 4YYZ). Several compounds (TS-897, TS-883, TS-945, and others) demonstrated Jamda Score values comparable to or exceeding that of the native ligand, indicating strong predicted binding affinity. Additional candidates were identified based on high pharmacophore similarity (>0.95). Among the 14 proposed compounds, four (IV-81, IV-91, IV-158) exhibited no cytotoxicity in HEK-293 cells (IC50 > 1024 µM). These findings support the potential of the synthesized azoloazine derivatives as novel 11β-HSD1 inhibitors for further in vitro and in vivo studies in osteoporosis therapy. Conclusion: As a result of this work, original azoloazine derivatives have been developed for further biological testing aimed at regulating the activity of 11β-hydroxysteroid dehydrogenase isoforms (11β-HSDs) for pharmacological correction of bone remodeling and osteoreparation disorders.

16 July 2025 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
ИКИван С. Коклин
Иван С. Коклин
PLPetr Lebedev
Petr Lebedev
AKAlim A. Kochkarov
Alim A. Kochkarov
OGOleg Gudyrev
Oleg Gudyrev
VGVladimir Gureev
Vladimir Gureev
MKMikhail Korokin
Mikhail Korokin
Введение: Остеопороз является важной медицинской и социальной проблемой общественного здравоохранения в стареющем или пожилом обществе, проблема фармакологической коррекции которой не решена на сегодняшний день. Материалы и методы: Обоснование данной идеи вытекает из наших предыдущих данных о роли 11β-ГСД 2-го типа в ремоделировании костной ткани и остеорепарации, в сочетании с контент-анализом и обзором литературы научных публикаций из баз данных PubMed, Scopus, КиберЛенинка, Google Scholar и ResearchGate. Результаты и обсуждение: Достигнутое сегодня понимание молекулярных механизмов костного гомеостаза позволяет существенно изменить и расширить парадигмы лечения и профилактики остеопороза. 11β-гидроксистероиддегидрогеназа 1-го типа (11β-HSD1) является ключевым метаболическим ферментом, который катализирует внутриклеточное превращение неактивных глюкокортикоидов в физиологически активные. Исследования, проведенные за последнее десятилетие, показали, что аномальная активность 11β--HSD1 вносит свой вклад в реализацию патогенетических звеньев, приводящих к ожирению, сахарному диабету 2 типа, метаболический синдрому и остеопорозу. Решить научную проблему регуляции активности изоформ 11β--гидроксистероиддегидрогеназ (11β-HSDs) и восстановления гомеостаза в ферментативной системе 11β--HSD1/11β--HSD2 предлагается путем разработки и применения оригинальных соединений-ингибиторов 11β-HSD1 азагетероциклического ряда. Заключение: Разработка соединений азагетероциклического ряда – ингибиторов 11β-HSD1 позволит выявить соединения – лекарственные кандидаты для фармакологической коррекции нарушений костного ремоделирования и остеорепарации.